T-cell-directed therapies in inflammatory bowel diseases

Clinical Science

Volumn 118, Issue 12, 2010, Pages 707-715

  Monteleone, Giovanni ^a   Caprioli, Flavio ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Crohn's disease; Cytokine; Inflammatory bowel disease (IBD); Interleukin; T cell; Tumour necrosis factor (TNF); Ulcerative colitis

Indexed keywords

ABATACEPT; ABT 874; ADALIMUMAB; ALICAFORSEN; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; INFLIXIMAB; MERCAPTOPURINE; NATALIZUMAB; TACROLIMUS; TOCILIZUMAB; USTEKINUMAB; VEDOLIZUMAB; VISILIZUMAB; GASTROINTESTINAL AGENT;

APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CROHN DISEASE; CYTOKINE PRODUCTION; ENTERITIS; FOOD AND DRUG ADMINISTRATION; HUMAN; INTESTINE FLORA; LAMINA PROPRIA; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MUCOSA INFLAMMATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; ULCERATIVE COLITIS; CELL PROLIFERATION; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MUCOSAL IMMUNITY;

APOPTOSIS; CELL PROLIFERATION; GASTROINTESTINAL AGENTS; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 77954082347     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20100027     Document Type: Review

References (77)

1. Strober, W., Fuss, I. and Mannon, P. (2007) The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 117, 514-521
2. Maynard, C. L. and Weaver, C. T. (2009) Intestinal effector T cells in health and disease. Immunity 31, 389-400
3. Van Assche, G. and Rutgeerts, P. (2005) Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G169-G174
4. Mudter, J. and Neurath, M. F. (2007) Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut 56, 293-303
5. Sturm, A., de Souza, H. S. and Fiocchi, C. (2008) Mucosal T cell proliferation and apoptosis in inflammatory bowel disease. Curr. Drug Targets 9, 381-387
6. Barnes, M. J. and Powrie, F. (2009) Regulatory T cells reinforce intestinal homeostasis. Immunity 31, 401-411
7. Lodes, M. J., Cong, Y., Elson, C. O., Mohamath, R., Landers, C. J., Targan, S. R., Fort, M. and Hershberg, R. M. (2004) Bacterial flagellin is a dominant antigen in Crohn disease. J. Clin. Invest. 113, 1296-1306
8. Ergin, A., Adam, T., Bussow, K., Thiel, A., Sieper, J. and Duchmann, R. (2008) Identification of the predominant antigenic epitopes in intestinal flora in IBD. Mucosal Immunol. 1, (Suppl. 1), S19-S23
9. Oyama, Y., Craig, R. M., Traynor, A. E., Quigley, K., Statkute, L., Halverson, A., Brush, M., Verda, L., Kowalska, B., Krosnjar, N. et al. (2005) Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 128, 552-563
10. Pospai, D., Rene, E., Fiasse, R., Farahat, K., Beaugery, L., Lammens, P., Reimund, C., Duclos, B., Le Quintrec, Y., Vandercam, B. and Mignon, M. (1998) Crohn's disease stable remission after human immunodeficiency virus infection. Dig. Dis. Sci. 43, 412-419
11. Delaporte, E. (2008) Immune-mediated inflammatory diseases and psoriasis. Ann. Dermatol. Venereol. 135, (Suppl. 4), S269-S274
12. Curtis, W. D., Schuman, B. M. and Griffin, Jr, J.W. (1992) Association of gluten-sensitive enteropathy and Crohn's colitis. Am. J. Gastroenterol. 87, 1634-1637
13. Cominelli, F. (2004) Cytokine-based therapies for Crohn's disease-new paradigms. N. Engl. J. Med. 351, 2045-2048
14. Hynes, R. O. (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 11-25
15. Tubridy, N., Behan, P. O., Capildeo, R., Chaudhuri, A., Forbes, R., Hawkins, C. P., Hughes, R. A., Palace, J., Sharrack, B., Swingler, R. et al. (1999) The effect of anti-α4 integrin antibody on brain lesion activity in MS. Neurology 53, 466-472
16. Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S. et al. (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353, 1912-1925
17. Targan, S. R., Feagan, B. G., Fedorak, R. N., Lashner, B. A., Panaccione, R., Present, D. H., Spehlmann, M. E., Rutgeerts, P. J., Tulassay, Z., Volfova, M. et al. (2007) Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132, 1672-1683 (Pubitemid 46695722)
18. Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W. and Rutgeerts, P. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353, 362-368
19. Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Pare, P., McDonald, J. W., Dube, R., Cohen, A., Steinhart, A. H., Landau, S. et al. (2005) Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N. Engl. J. Med. 352, 2499-2507
20. Feagan, B. G., Greenberg, G., Wild, G., McDonald, J. W., Fedorak, R., Pare, P., Kishimoto, K., Gutierrez-Ramos, J. C. and Krop, J. (2003) Efficacy and safety of a humanized α4β7 antibody in active Crohn's disease (CD). Gastroenterology 124, A25-A26
21. Yacyshyn, B. R., Bowen-Yacyshyn, M. B., Jewell, L., Tami, J. A., Bennett, C. F., Kisner, D. L. and Shanahan, Jr, W. R. (1998) A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114, 1133-1142
22. Yacyshyn, B., Chey, W. Y., Wedel, M. K., Yu, R. Z., Paul, D. and Chuang, E. (2007) A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin. Gastroenterol. Hepatol. 5, 215-220
23. Keshav, S., Ungashe, S., Zheng, W., Bekker, P., Wright, K. and Schall, T. (2007) Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease. Gastroenterology 137, A157
24. Liu, J. O. (2009) Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation. Immunol. Rev. 228, 184-198
25. Okamura, H., Aramburu, J., Garcia-Rodriguez, C., Viola, J. P., Raghavan, A., Tahiliani, M., Zhang, X., Qin, J., Hogan, P. G. and Rao, A. (2000) Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol. Cell 6, 539-550
26. Shaw, J. P., Utz, P. J., Durand, D. B., Toole, J. J., Emmel, E. A. and Crabtree, G. R. (1988) Identification of a putative regulator of early T cell activation genes. Science 241, 202-205
27. Present, D. H. and Lichtiger, S. (1994) Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig. Dis. Sci. 39, 374-380
28. Campbell, S., Travis, S. and Jewell, D. (2005) Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur. J. Gastroenterol. Hepatol. 17, 79-84
29. Sandborn, W. J. (2001) Cyclosporine in ulcerative colitis: state of the art. Acta Gastroenterol. Belg. 64, 201-204
30. Sandborn, W. J., Present, D. H., Isaacs, K. L., Wolf, D. C., Greenberg, E., Hanauer, S. B., Feagan, B. G., Mayer, L., Johnson, T., Galanko, J. et al. (2003) Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 125, 380-388
31. Ogata, H., Matsui, T., Nakamura, M., Iida, M., Takazoe, M., Suzuki, Y. and Hibi, T. (2006) A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 55, 1255-1262
32. Van Assche, G., Sandborn, W. J., Feagan, B. G., Salzberg, B. A., Silvers, D., Monroe, P. S., Pandak, W. M., Anderson, F. H., Valentine, J. F., Wild, G. E. et al. (2006) Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 55, 1568-1574
33. Creed, T. J., Norman, M. R., Probert, C. S., Harvey, R. F., Shaw, I. S., Smithson, J., Anderson, J., Moorghen, M., Gupta, J., Shepherd, N. A. et al. (2003) Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment. Pharmacol. Ther. 18, 65-75
34. Creed, T. J., Probert, C. S., Norman, M. N., Moorghen, M., Shepherd, N. A., Hearing, S. D. and Dayan, C. M. (2006) Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment. Pharmacol. Ther. 23, 1435-1442
35. Boirivant, M., Marini, M., Di Felice, G., Pronio, A. M., Montesani, C., Tersigni, R. and Strober, W. (1999) Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 116, 557-565 (Pubitemid 29106763)
36. Monteleone, I., Monteleone, G., Fina, D., Caruso, R., Petruzziello, C., Calabrese, E., Biancone, L. and Pallone, F. (2006) A functional role of flip in conferring resistance of Crohn's disease lamina propria lymphocytes to FAS-mediated apoptosis. Gastroenterology 130, 389-397 (Pubitemid 43202038)
37. Caprioli, F., Stolfi, C., Caruso, R., Fina, D., Sica, G., Biancone, L., Pallone, F. and Monteleone, G. (2008) Transcriptional and post-translational regulation of Flip, an inhibitor of Fas-mediated apoptosis, in human gut inflammation. Gut 57, 1674-1680
38. Atreya, R., Mudter, J., Finotto, S., Mullberg, J., Jostock, T., Wirtz, S., Schutz, M., Bartsch, B., Holtmann, M., Becker, C. et al. (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med. 6, 583-588
39. + T cells through phosphatidylinositol 3-kinase/Akt signaling pathway. J Immunol. 169, 3637-3643
40. Sandborn, W., Sutherland, L., Pearson, D., May, G., Modigliani, R. and Prantera, C. (2000) Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease, Cochrane Database Syst. Rev., CD000545 doi:10.1002/14651858. CD000545.pub2
41. Timmer, A., McDonald, J.W. and Macdonald, J. K. (2007) Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database Syst. Rev., CD000478 doi:10.1002/14651858.CD000478.pub2
42. + T lymphocytes. J. Clin. Invest. 111, 1133-1145
43. Ben-Horin, S., Goldstein, I., Fudim, E., Picard, O., Yerushalmi, Z., Barshack, I., Bank, I., Goldschmid, Y., Meir, S. B., Mayer, L. and Chowers, Y. (2009) Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines. Gut 58, 396-403
44. Targan, S. R., Hanauer, S. B., van Deventer, S. J., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F. and Rutgeerts, P. J. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N. Engl. J. Med. 337, 1029-1035
45. Hyams, J. S., Markowitz, J. and Wyllie, R. (2000) Use of infliximab in the treatment of Crohn's disease in children and adolescents. J. Pediatr. 137, 192-196 (Pubitemid 30659226)
46. Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R. et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462-2476
47. Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L. et al. (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340, 1398-1405
48. Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E. et al. (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350, 876-885
49. Colombel, J. F., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D. and Pollack, P. F. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132, 52-65
50. Colombel, J. F., Schwartz, D. A., Sandborn, W. J., Kamm, M. A., D'Haens, G., Rutgeerts, P., Enns, R., Panaccione, R., Schreiber, S., Li, J. et al. (2009) Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 58, 940-948
51. ten Hove, T., van Montfrans, C., Peppelenbosch, M. P. and van Deventer, S. J. (2002) Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50, 206-211
52. Scallon, B. J., Moore, M. A., Trinh, H., Knight, D. M. and Ghrayeb, J. (1995) Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7, 251-259
53. Di Sabatino, A., Ciccocioppo, R., Cinque, B., Millimaggi, D., Morera, R., Ricevuti, L., Cifone, M. G. and Corazza, G. R. (2004) Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 53, 70-77 (Pubitemid 38083013)
54. Lugering, A., Schmidt, M., Lugering, N., Pauels, H. G., Domschke, W. and Kucharzik, T. (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121, 1145-1157 (Pubitemid 33022095)
55. Mitoma, H., Horiuchi, T., Hatta, N., Tsukamoto, H., Harashima, S., Kikuchi, Y., Otsuka, J., Okamura, S., Fujita, S. and Harada, M. (2005) Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α. Gastroenterology 128, 376-392
56. Carpenter, P. A., Appelbaum, F. R., Corey, L., Deeg, H. J., Doney, K., Gooley, T., Krueger, J., Martin, P., Pavlovic, S., Sanders, J. et al. (2002) A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99, 2712-2719
57. Yu, Q. T., Saruta, M. and Papadakis, K. A. (2008) Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin. Immunol. 127, 322-329
58. Plevy, S., Salzberg, B., Van Assche, G., Regueiro, M., Hommes, D., Sandborn, W., Hanauer, S., Targan, S., Mayer, L., Mahadevan, U. et al. (2007) A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 133, 1414-1422
59. Baumgart, D. C., Targan, S. R., Dignass, A. U., Mayer, L., Assche, G. V., Hommes, D.W., Hanauer, S. B., Mahadevan, U., Reinisch, W., Plevy, S. E. et al. (2009) Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm, Bowel Dis., doi: 10.1002/ibd.21084
60. Mudter, J. and Neurath, M. F. (2007) Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm. Bowel Dis. 13, 1016-1023
61. Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., Nishimoto, N. et al. (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126, 989-996
62. Tan, P., Anasetti, C., Hansen, J. A., Melrose, J., Brunvand, M., Bradshaw, J., Ledbetter, J. A. and Linsley, P. S. (1993) Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J. Exp. Med. 177, 165-173
63. Krummel, M. F. and Allison, J. P. (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183, 2533-2540
64. MacDonald, T. T., Hutchings, P., Choy, M. Y., Murch, S. and Cooke, A. (1990) Tumour necrosis factor-α and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin. Exp. Immunol. 81, 301-305
65. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157, 1261-1270
66. Fuss, I. J., Heller, F., Boirivant, M., Leon, F., Yoshida, M., Fichtner-Feigl, S., Yang, Z., Exley, M., Kitani, A., Blumberg, R. S. et al. (2004) Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113, 1490-1497
67. Brand, S. (2009) Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58, 1152-1167
68. Pallone, F. and Monteleone, G. (1998) Interleukin 12 and Th1 responses in inflammatory bowel disease. Gut 43, 735-736 (Pubitemid 28539644)
69. Kobayashi, T., Okamoto, S., Hisamatsu, T., Kamada, N., Chinen, H., Saito, R., Kitazume, M. T., Nakazawa, A., Sugita, A., Koganei, K. et al. (2008) IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57, 1682-1689
70. Neurath, M. F., Fuss, I., Kelsall, B. L., Stuber, E. and Strober, W. (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182, 1281-1290
71. Mannon, P. J., Fuss, I. J., Mayer, L., Elson, C. O., Sandborn, W. J., Present, D., Dolin, B., Goodman, N., Groden, C., Hornung, R. L. et al. (2004) Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351, 2069-2079
72. Sandborn, W. J., Feagan, B. G., Fedorak, R. N., Scherl, E., Fleisher, M. R., Katz, S., Johanns, J., Blank, M. and Rutgeerts, P. (2008) A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135, 1130-1141
73. Fuss, I. J., Becker, C., Yang, Z., Groden, C., Hornung, R. L., Heller, F., Neurath, M. F., Strober, W. and Mannon, P. J. (2006) Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm. Bowel Dis. 12, 9-15
74. Elson, C. O., Cong, Y., Weaver, C. T., Schoeb, T. R., McClanahan, T. K., Fick, R. B. and Kastelein, R. A. (2007) Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 132, 2359-2370 (Pubitemid 46890867)
75. Wada, Y., Lu, R., Zhou, D., Chu, J., Przewloka, T., Zhang, S., Li, L., Wu, Y., Qin, J., Balasubramanyam, V. et al. (2007) Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood 109, 1156-1164
76. Sands, B. E., Jacobson, E. W., Sylwestrowicz, T., Younes, Z., Dryden, G., Fedorak, R. and Greenbloom, S. (2009) Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm, Bowel Dis., doi 10.1002/ibd.21159
77. Miossec, P., Korn, T. and Kuchroo, V. K. (2009) Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361, 888-898